Literature DB >> 24629370

Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma.

Rachel L Kyllo1, Mary Kendall Parker2, Ilana Rosman3, Amy C Musiek4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24629370     DOI： 10.1016/j.jaad.2013.11.022

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  9 in total

1.  Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome.

Authors:  A V Marzano; D Fanoni; E Antiga; P Quaglino; M Caproni; C Crosti; P L Meroni; M Cugno
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

Review 2.  Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.

Authors:  Shannon K Quirk; Anna K Shure; Devendra K Agrawal
Journal:  Transl Res       Date:  2015-06-11       Impact factor: 7.012

3.  Aseptic Abscess Syndrome: Clinical Characteristics, Associated Diseases, and up to 30 Years' Evolution Data on a 71-Patient Series.

Authors:  Ludovic Trefond; Camille Frances; Nathalie Costedoat-Chalumeau; Jean-Charles Piette; Julien Haroche; Laurent Sailler; Souad Assaad; Jean-François Viallard; Patrick Jego; Arnaud Hot; Jerome Connault; Jean-Marc Galempoix; Elisabeth Aslangul; Nicolas Limal; Fabrice Bonnet; Stanislas Faguer; Olivier Chosidow; Christophe Deligny; François Lifermann; Alexandre Thibault Jacques Maria; Bruno Pereira; Olivier Aumaitre; Marc André
Journal:  J Clin Med       Date:  2022-06-25       Impact factor: 4.964

Review 4.  Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.

Authors:  Samantha R Ellis; Aren T Vierra; Jillian W Millsop; Mario E Lacouture; Maija Kiuru
Journal:  J Am Acad Dermatol       Date:  2020-04-29       Impact factor: 11.527

Review 5.  Insights Into the Pathogenesis of Sweet's Syndrome.

Authors:  Michael S Heath; Alex G Ortega-Loayza
Journal:  Front Immunol       Date:  2019-03-12       Impact factor: 7.561

6.  Active repurposing of drug candidates for melanoma based on GWAS, PheWAS and a wide range of omics data.

Authors:  Ali Khosravi; B Jayaram; Bahram Goliaei; Ali Masoudi-Nejad
Journal:  Mol Med       Date:  2019-06-20       Impact factor: 6.354

7.  "Skin rashes" and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management.

Authors:  Pietro Sollena; Simone Cappilli; Francesco Federico; Giovanni Schinzari; Giampaolo Tortora; Ketty Peris
Journal:  Hum Vaccin Immunother       Date:  2021-03-24       Impact factor: 4.526

8.  Drug eruptions with novel targeted therapies - immune checkpoint and EGFR inhibitors.

Authors:  Isabella Pospischil; Wolfram Hoetzenecker
Journal:  J Dtsch Dermatol Ges       Date:  2021-11       Impact factor: 5.231

Review 9.  Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis.

Authors:  Anne Bertrand; Marie Kostine; Thomas Barnetche; Marie-Elise Truchetet; Thierry Schaeverbeke
Journal:  BMC Med       Date:  2015-09-04       Impact factor: 8.775
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.